VANCOUVER, BC, April 15, 2025 /PRNewswire/ – A new U.S. Neurological Devices Market Report provides essential insights for CEOs, CFOs, product and marketing managers in the neurology and neurosurgery sectors, helping executives navigate regulatory uncertainty, enabling product teams to adapt to emerging technologies like AI and neuromodulation, and equipping commercial leaders with data to uncover high-growth segments and revenue opportunities in a rapidly evolving neurological devices market.
Produced by iData Research, a leading medical consulting and market research firm, this comprehensive neurology report offers deep analysis of technological disruption, regulatory shifts, and emerging clinical needs impacting profitability and competitive advantage in the neurological devices market.
“As neurology evolves through AI, minimally invasive neuromodulation, and real-time stroke treatment, market leaders must act fast,” said Dr. Kamran Zamanian, CEO of iData Research. “This report arms decision-makers with the intelligence needed to compete in a highly innovative and patient-driven neurology field.”
From Therapy to Tech: The New Era of Neurological Devices in the U.S.
Driven by innovations in neuromodulation, neurovascular intervention, and diagnostic AI, the U.S. neurological devices market exceeded $7.6 billion in 2024 and is forecasted to reach nearly $10 billion by 2030.
Key growth areas include:
Key Insights from the Report:
Who Should Read This Report?
This report is designed for CEOs, CFOs, product and marketing managers, as well as strategic decision-makers within the neurology and neurosurgery sectors looking to make data-driven decisions in the high-growth neurological devices field.
Explore the Market Report
Access a Sample of the Full 2025–2031 U.S. Neurological Devices Market Report, or contact marketing at marketing@idataresearch.net to learn more and see detailed insights into market drivers, growth projections, and strategic opportunities.
About iData Research
iData Research has been a leader in market intelligence for the medical devices industry for over 20 years, delivering data-driven insights that help companies mitigate market risks, optimize pricing strategies, and uncover new revenue opportunities.
Learn more at https://idataresearch.com/
SOURCE iData Research Inc.
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…
Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response…